カレントテラピー　29-7　サンプル page 20/28

このページは カレントテラピー　29-7　サンプル の電子ブックに掲載されている20ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
参考文献1）Hoieggen A, Alderman MH, Kjeldsen SE, et al：The impactof serum uric acid on cardiovascular outcomes in the LIFEstudy. Kidney Int 65：1041-1049, 20042）Athyros VG, Mikhailidis DP, Papageorg....

参考文献1）Hoieggen A, Alderman MH, Kjeldsen SE, et al：The impactof serum uric acid on cardiovascular outcomes in the LIFEstudy. Kidney Int 65：1041-1049, 20042）Athyros VG, Mikhailidis DP, Papageorgiou AA, et al：Theeffect of statins versus untreated dyslipidaemia on renalfunction in patients with coronary heart disease. A subgroupanalysis of the Greek atorvastatin and coronary heart diseaseevaluation（GREACE）study. J Clin Pathol 57：728 -734,20043）Verdecchia P, Schillaci G, Reboldi G, et al：Relation betweenserum uric acid and risk of cardiovascular disease in essentialhypertension. The PIUMA study. Hypertension 36：1072-1078, 20004）Enomoto A, Kimura H, Chairoungdua A, et al：Molecularidentification of a renal urate anion exchanger that regulatesblood urate levels. Nature 417：447-452, 20025）Corry DB, Eslami P, Yamamoto K, et al：Uric acid stimulatesvascular smooth muscle cell proliferation and oxidative stressvia the vascular renin -angiotensin system. J Hypertens 26：269 -275, 20086）Yamamoto Y, Ogino K, Igawa G, et al：Allopurinol reducesneointimal hyperplasia in the carotid artery ligation model inspontaneously hypertensive rats. Hypertens Res 29：915 -921, 20067）Kato M, Hisatome I, Tomikura Y, et al：Status of endothelialdependent vasodilation in patients with hyperuricemia. Am JCardiol 96：1576-1578, 20058）Bickel C, Rupprecht HJ, Blankenberg S, et al：Serum uricacid as an independent predictor of mortality in patientswith angiographically proven coronary artery disease. Am JCardiol 89：12-17, 20029）Kojima S, Sakamoto T, Ishihara M, et al：Prognostic usefulnessof serum uric acid after acute myocardial infarction（theJapanese Acute Coronary Syndrome Study）. Am J Cardiol96：489 -495, 200510）Ogino K, Osaki S, Noguchi N, et al：Nicorandil suppressedmyocardial purine metabolism during exercise in patientswith angina pectoris. Eur J Clin Pharmacol 48：189 -194, 199511）Noman A, Ang DS, Ogston S, et al：Effect of high-dose allopurinolon exercise in patients with chronic stable angina：arandomised, placebo controlled crossover trial. Lancet 375：2161-2167, 201012）Anker SD, Doehner W, Rauchhaus M, et al：Uric acid andsurvival in chronic heart failure：validation and applicationin metabolic, functional, and hemodynamic staging.Circulation 107：1991-1997, 200313）Friedel HA, Buckley MM：Torasemide. A review of its pharmacologicalproperties and therapeutic potential. Drugs 41：81 -103, 199114）Doehner W, Anker SD：Uric acid in chronic heart failure.Semin Nephrol 25：61-66, 200515）Ogino K, Kato M, Furuse Y, et al：Uric acid -lowering treatmentwith benzbromarone in patients with heart failure：adouble -blind placebo -controlled crossover preliminarystudy. Circ Heart Fail 3：73-81, 201016）Doehner W, Schoene N, Rauchhaus M, et al：Effects of xanthineoxidase inhibition with allopurinol on endothelial functionand peripheral blood flow in hyperuricemic patientswith chronic heart failure：results from 2 placebo-controlledstudies. Circulation 105：2619-2624, 200217）Gavin AD, Struthers AD：Allopurinol reduces B -type natriureticpeptide concentrations and haemoglobin but does notalter exercise capacity in chronic heart failure. Heart 91：749 -753, 200518）Struthers AD, Donnan PT, Lindsay P, et al：Effect of allopurinolon mortality and hospitalisations in chronic heart failure：aretrospective cohort study. Heart 87：229-234, 200219）Hare JM, Mangal B, Brown J, et al：Impact of oxypurinol inpatients with symptomatic heart failure. Results of the OPT -CHF study. J Am Coll Cardiol 51：2301-2309, 200830592